INDIANAPOLIS (WISH) — Indianapolis-based Lilly said Thursday its daily obesity pill, orforglipron, has shown “positive results” in a late-stage trial. Patients taking orforglipron, an oral GLP-1 ...

Shares of Eli Lilly plummeted 14% on Thursday, pacing what would be the stock’s largest loss in decades after the pharmaceutical giant unveiled data for its obesity treatment pill that fell behind ...

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the year. By Gina Kolata People who were overweight or had obesity lost a ...

(Reuters) -Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic ...